About Gamma-aminobutyric acid receptor subunit rho-3
Gamma-aminobutyric acid receptor subunit rho-3 (GABRR3) is a protein
from Homo sapiens identified by UniProt accession
A8MPY1, 467 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Gamma-aminobutyric acid receptor subunit rho-3 |
|---|
| UniProt accession | A8MPY1 |
|---|
| Gene | GABRR3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 467 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (6)
Diseases linked to this target (Open Targets).
- Spinal cord injury · score 0.01
- essential thrombocythemia · score 0.01
- migraine disorder · score 0.00
- hepatocellular carcinoma · score 0.00
- myeloid sarcoma · score 0.00
- Neurodevelopmental delay · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A8MPY1-F1 | alphafold | PREDICTED | 75.84 | — |
Amino-acid sequence (467 residues)
MVLAFQLVSF TYIWIILKPN VCAASNIKMT HQRCSSSMKQ TCKQETRMKK DDSTKARPQK YEQLLHIEDN DFAMRPGFGG SPVPVGIDVH VESIDSISET NMDFTMTFYL RHYWKDERLS FPSTANKSMT FDHRLTRKIW VPDIFFVHSK RSFIHDTTME NIMLRVHPDG NVLLSLRITV SAMCFMDFSR FPLDTQNCSL ELESYAYNED DLMLYWKHGN KSLNTEEHMS LSQFFIEDFS ASSGLAFYSS TGWYNRLFIN FVLRRHVFFF VLQTYFPAIL MVMLSWVSFW IDRRAVPARV SLGITTVLTM STIITAVSAS MPQVSYLKAV DVYLWVSSLF VFLSVIEYAA VNYLTTVEER KQFKKTGKIS RMYNIDAVQA MAFDGCYHDS EIDMDQTSLS LNSEDFMRRK SICSPSTDSS RIKRRKSLGG HVGRIILENN HVIDTYSRIL FPIVYILFNL FYWGVYV
Explore Gamma-aminobutyric acid receptor subunit rho-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets